抗逆转录病毒药物_HIV和HBV共同患者_生命危险

Posted 2020-06-16

Antiretrovirals: HIV, hepatic impairment and HBV/HCV

European Union — During 2002, the European Medicines Agency (EMEA) requested the marketing authorisation holders for all licensed antiretroviral medicinal products in Europe to conduct a retrospective review from clinical trials and post marketing data in HIV patients with hepatic impairment and/or HBV/HCV co-infection, with the aim to review pharmacokinetic and safety data, and propose measures to improve the availability of relevant data from these patients. After an assessment of initial responses in April 2004, marketing authorization holders jointly established the HIV/Hepatitis Co-infection Cohort Collaboration (HIVCO) to plan how to obtain information on the hepatic safety of highly active antiretroviral treatment (HAART) in co-infected patients. At the CHMP and Pharmacovigilance Working party meeting in June 2005, the CHMP endorsed the HIVCO proposal to use the ongoing Study on Data Collection on Adverse Events of Anti-HIV Drugs for the evaluation of liver related death in co-infected patients. Reference: EMEA public statement. 5 August 2005. EMEA/CHMP/249537/2005 on http://www.emea.eu.int